Ashland's sale process advances as buyback and new product offset weak additives
Takeover bids now being collected Ashland is collecting takeover bids this month, with Apollo, Carlyle and others interested. Activist pressure has pushed the company toward a possible sale, and reports suggest a deal could value shares well above recent levels. This keeps a buyout premium in the stock.
The sale process is the biggest force behind ASH's price right now, directly tied to activist pressure and reported bid interest.
New $1 billion buyback doubles prior plan Ashland announced a new $1 billion share repurchase plan, twice its previous authorization. Buying back stock can support the share price by reducing the number of shares and signaling management's confidence, even as the stock had slipped recently.
The buyback is a fresh capital-return action that directly supports the stock price and shows management's response to recent weakness.
New oral biologics ingredient launched Ashland launched Permexa sodium caprate, an ingredient that helps turn injectable drugs into pills, targeting the fast-growing GLP-1 and metabolic markets. Partners are already testing it. If it wins commercial contracts, it could add a new long-term growth stream.
This is a new product that could drive future revenue growth in Ashland's strongest division, Life Sciences.
Solid sales but profit pressure persists Third-quarter sales rose 7% to $497 million and full-year guidance was reaffirmed, but adjusted EBITDA fell 4% and EPS growth outlook was trimmed due to higher taxes and costs. Weak Specialty Additives and Intermediates continue to weigh on overall profitability.
This explains the underlying business performance that both supports and limits the stock, balancing the positive sale and buyback news.